Let's list a few bullet points about ARX for the start of the new year. For anyone interested in this company, do your own research and you may find evidence for the followings:
-Solid cash position
-Approx breakeven
-Zero debt
-Proven financial discipline
-Expanding product pipeline
-Great products backed by clinical research
-High revenue growth
-Incredible high gross margin
-High quality customers (eg. large hospitals and group purchasers)
-Defensive sector
-No-nonsense, down-to-earth management
DYOR and GLTA.
Feel free to add on.
Let's list a few bullet points about ARX for the start of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
-0.005(0.81%) |
Mkt cap ! $210.4M | |||
| Open | High | Low | Value | Volume |
| 62.5¢ | 62.5¢ | 60.5¢ | $101.9K | 165.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7000 | 60.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.5¢ | 3169 | 1 |
View Market Depth
| Last trade - 16.10pm 11/08/2025 (20 minute delay) ? |
| ARX (ASX) Chart |